Mohamad Ayoubi, MD
Hematology & Oncology · Defiance, OHNPI 1962461822
Payments from drug & device makers
Across 262 payments — averaging $4937.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.2M
- AstraZeneca$45K
- E.r. Squibb & Sons, L.L.C.$479
- Genentech USA, Inc.$453
- Pharmacyclics LLC, An Abbvie Company$311
- Johnson & Johnson$212
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,52590%
- Education$39710%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 81 | $1,244,950 |
| AstraZeneca(2 entities) | 22 | $45,419 |
| E.r. Squibb & Sons, L.L.C. | 27 | $479 |
| Genentech USA, Inc. | 23 | $453 |
| Pharmacyclics LLC, An Abbvie Company | 8 | $311 |
| Johnson & Johnson(2 entities) | 9 | $212 |
| Bayer | 9 | $167 |
| Amgen | 9 | $162 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $159 |
| Novartis | 8 | $157 |
| Incyte Corporation | 4 | $144 |
| Bristol Myers Squibb | 7 | $141 |
| Lilly USA, LLC | 6 | $124 |
| Novocure Inc. | 1 | $121 |
| Seagen Inc. | 9 | $115 |
| GSK | 1 | $81 |
| Sanofi | 4 | $71 |
| Exelixis Inc. | 3 | $49 |
| Mylan Specialty L.p. | 2 | $47 |
| Eisai Inc. | 2 | $43 |
| Sunovion Pharmaceuticals Inc. | 3 | $39 |
| Gilead | 2 | $28 |
| Amarin Pharma, Inc. | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Emmaus Medical, Inc. | 1 | $20 |
| Adaptive Biotechnologies Corporation | 1 | $19 |
| Novo Nordisk | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Epizyme, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Coherus Oncology, Inc. | 1 | $15 |
| Pfizer | 1 | $12 |
| Puma Biotechnology, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optune$121
How this compares
$1,293,711 in reported general payments places this provider in the 90th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 35 | $470,409 |
| JakafiRuxolitinib Phosphate | 12 | $191,323 |
| VerzenioAbemaciclib | 12 | $183,857 |
| ErleadaApalutamide | 11 | $159,469 |
| LynparzaOlaparib | 12 | $108,133 |
| Imatinib Mesylate | 19 | $57,284 |
| EliquisApixaban | 40 | $39,076 |
| XareltoRivaroxaban | 16 | $16,194 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 88 | $3,289 |
| Anastrozole | 95 | $1,248 |
| Prochlorperazine Maleate | 31 | $1,059 |
| Ondansetron OdtOndansetron | 31 | $879 |
| Oxycodone Hcl | 28 | $714 |
| Morphine Sulfate ErMorphine Sulfate | 15 | $538 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 16 | $523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $144 | $191,32312 claims |
| Lilly USA, LLCVerzenio | $124 | $183,85712 claims |
| Johnson & JohnsonErleada, Xarelto | $212 | $175,66227 claims |
| AstraZenecaLynparza | $45,419 | $108,13312 claims |
| PfizerEliquis | $12 | $39,07640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Defiance
- Afshin DowlatiCleveland$25.1M
- Brian HillCleveland$11.6M
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- Christopher HoimesCleveland$7.5M
- Balazs HalmosCleveland$7M
- David WaterhouseCincinnati$5.7M
- Dale ShepardCleveland$5.1M
- Paolo CaimiCleveland$4.2M
- Allison WinterCleveland$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.